City State Bank’s Denali Therapeutics DNLI Stock Holding History

City State Bank’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.43K	Hold	250	–	–	﹤0.01%	609
2026 Q1	$4.8K	Hold	250	–	–	﹤0.01%	616
2025 Q4	$4.13K	Hold	250	–	–	﹤0.01%	626
2025 Q3	$3.63K	Hold	250	–	–	﹤0.01%	627
2025 Q2	$3.5K	Hold	250	–	–	﹤0.01%	632
2025 Q1	$3.4K	Hold	250	–	–	﹤0.01%	633
2024 Q4	$5.09K	Hold	250	–	–	﹤0.01%	576
2024 Q3	$7.28K	Hold	250	–	–	﹤0.01%	527
2024 Q2	$5.8K	Hold	250	–	–	﹤0.01%	541
2024 Q1	$5K	Hold	250	–	–	﹤0.01%	569
2023 Q4	$5K	Hold	250	–	–	﹤0.01%	549
2023 Q3	$5K	Hold	250	–	–	﹤0.01%	546
2023 Q2	$7K	Hold	250	–	–	﹤0.01%	521
2023 Q1	$6K	Hold	250	–	–	﹤0.01%	535
2022 Q4	$7K	Hold	250	–	–	﹤0.01%	483
2022 Q3	$8K	Hold	250	–	–	0.01%	457
2022 Q2	$7K	Hold	250	–	–	﹤0.01%	488
2022 Q1	$8K	Hold	250	–	–	﹤0.01%	497
2021 Q4	$11K	Buy	+250	New	+$11.8K	0.01%	448

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

City State Bank's DNLI Position: Q2 2026 in Review

City State Bank held its Denali Therapeutics (DNLI) position steady in Q2 2026 at 250 shares worth $6.43K. The position accounts for ﹤0.01% of the portfolio, ranked #609.

City State Bank first reported a position in DNLI in Q4 2021 and has held it in 19 quarters since. The position peaked at $11K in Q4 2021. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

City State Bank held 250 shares of Denali Therapeutics worth $6.43K as of Q2 2026.
City State Bank left its Denali Therapeutics share count unchanged in Q2 2026.
Denali Therapeutics made up ﹤0.01% of City State Bank's portfolio in Q2 2026, its #609 holding.
City State Bank first reported a position in Denali Therapeutics in Q4 2021 and has held it in 19 quarters since.
City State Bank's Denali Therapeutics position peaked at $11K in Q4 2021.
292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on City State Bank's 13F filing for Q2 2026, filed 14 Jul 2026.